Aprea Therapeutics (APRE) Competitors

$0.84 +0.00 (+0.29%)

Closing price 04:00 PM Eastern

Extended Trading

$0.81 -0.04 (-4.41%)

As of 05:43 PM Eastern

APRE vs. ATHE, HOWL, ALGS, RNXT, and INMB

Should you be buying Aprea Therapeutics stock or one of its competitors? The main competitors of Aprea Therapeutics include Alterity Therapeutics (ATHE), Werewolf Therapeutics (HOWL), Aligos Therapeutics (ALGS), RenovoRx (RNXT), and INmune Bio (INMB). These companies are all part of the "pharmaceutical products" industry.

How does Aprea Therapeutics compare to Alterity Therapeutics?

Aprea Therapeutics (NASDAQ:APRE) and Alterity Therapeutics (NASDAQ:ATHE) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, media sentiment, risk, analyst recommendations, institutional ownership, profitability, valuation and earnings.

: Alterity Therapeutics has lower revenue, but higher earnings than Aprea Therapeutics.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Aprea Therapeutics $290K 36.00 -$12.60M -$1.98 N/A
Alterity Therapeutics N/A N/A -$7.87M N/A N/A
: Alterity Therapeutics has a net margin of 0.00% compared to Aprea Therapeutics' net margin of -4,405.59%. Alterity Therapeutics' return on equity of 0.00% beat Aprea Therapeutics' return on equity.
Company Net Margins Return on Equity Return on Assets
Aprea Therapeutics -4,405.59% -96.33% -74.35%
Alterity Therapeutics N/A N/A N/A
: Aprea Therapeutics presently has a consensus price target of $4.10, indicating a potential upside of 386.24%. Given Aprea Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Aprea Therapeutics is more favorable than Alterity Therapeutics.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Aprea Therapeutics
1 Sell rating(s)
1 Hold rating(s)

2 Buy rating(s)

0 Strong Buy rating(s)
2.25
Alterity Therapeutics
1 Sell rating(s)

1 Hold rating(s)

1 Buy rating(s)

0 Strong Buy rating(s)
2.00
: 34.2% of Aprea Therapeutics shares are held by institutional investors. Comparatively, 2.1% of Alterity Therapeutics shares are held by institutional investors. 13.6% of Aprea Therapeutics shares are held by insiders. Comparatively, 38.8% of Alterity Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
: Aprea Therapeutics has a beta of 1.48, indicating that its share price is 48% more volatile than the S&P 500. Comparatively, Alterity Therapeutics has a beta of 0.34, indicating that its share price is 66% less volatile than the S&P 500.
: In the previous week, Aprea Therapeutics and Aprea Therapeutics both had 1 articles in the media. Aprea Therapeutics' average media sentiment score of 0.00 beat Alterity Therapeutics' score of -0.43 indicating that Aprea Therapeutics is being referred to more favorably in the media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Aprea Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Alterity Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aprea Therapeutics	$290K	36.00	-$12.60M	-$1.98	N/A
Alterity Therapeutics	N/A	N/A	-$7.87M	N/A	N/A

Company	Net Margins	Return on Equity	Return on Assets
Aprea Therapeutics	-4,405.59%	-96.33%	-74.35%
Alterity Therapeutics	N/A	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aprea Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Alterity Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aprea Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Alterity Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Aprea Therapeutics beats Alterity Therapeutics on 7 of the 12 factors compared between the two stocks.

How does Aprea Therapeutics compare to Werewolf Therapeutics?

Werewolf Therapeutics (NASDAQ:HOWL) and Aprea Therapeutics (NASDAQ:APRE) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, dividends, profitability, earnings, valuation, institutional ownership, analyst recommendations and media sentiment.

: 64.8% of Werewolf Therapeutics shares are owned by institutional investors. Comparatively, 34.2% of Aprea Therapeutics shares are owned by institutional investors. 23.6% of Werewolf Therapeutics shares are owned by insiders. Comparatively, 13.6% of Aprea Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
: In the previous week, Werewolf Therapeutics had 8 more articles in the media than Aprea Therapeutics. MarketBeat recorded 9 mentions for Werewolf Therapeutics and 1 mentions for Aprea Therapeutics. Aprea Therapeutics' average media sentiment score of 0.00 beat Werewolf Therapeutics' score of -0.71 indicating that Aprea Therapeutics is being referred to more favorably in the news media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Werewolf Therapeutics
2 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Negative
Aprea Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
: Aprea Therapeutics has lower revenue, but higher earnings than Werewolf Therapeutics. Werewolf Therapeutics is trading at a lower price-to-earnings ratio than Aprea Therapeutics, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Werewolf Therapeutics $1.88M 17.31 -$60.82M -$1.36 N/A
Aprea Therapeutics $290K 36.00 -$12.60M -$1.98 N/A
: Werewolf Therapeutics has a net margin of 0.00% compared to Aprea Therapeutics' net margin of -4,405.59%. Aprea Therapeutics' return on equity of -96.33% beat Werewolf Therapeutics' return on equity.
Company Net Margins Return on Equity Return on Assets
Werewolf Therapeutics N/A -158.82% -69.75%
Aprea Therapeutics -4,405.59% -96.33% -74.35%
: Werewolf Therapeutics has a beta of 0.41, indicating that its stock price is 59% less volatile than the S&P 500. Comparatively, Aprea Therapeutics has a beta of 1.48, indicating that its stock price is 48% more volatile than the S&P 500.
: Werewolf Therapeutics currently has a consensus price target of $3.75, indicating a potential upside of 459.95%. Aprea Therapeutics has a consensus price target of $4.10, indicating a potential upside of 386.24%. Given Werewolf Therapeutics' higher probable upside, analysts clearly believe Werewolf Therapeutics is more favorable than Aprea Therapeutics.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Werewolf Therapeutics
1 Sell rating(s)
4 Hold rating(s)

2 Buy rating(s)

0 Strong Buy rating(s)
2.14
Aprea Therapeutics
1 Sell rating(s)

1 Hold rating(s)

2 Buy rating(s)

0 Strong Buy rating(s)
2.25

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Werewolf Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Negative
Aprea Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Werewolf Therapeutics	$1.88M	17.31	-$60.82M	-$1.36	N/A
Aprea Therapeutics	$290K	36.00	-$12.60M	-$1.98	N/A

Company	Net Margins	Return on Equity	Return on Assets
Werewolf Therapeutics	N/A	-158.82%	-69.75%
Aprea Therapeutics	-4,405.59%	-96.33%	-74.35%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Werewolf Therapeutics	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14
Aprea Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Summary

Werewolf Therapeutics beats Aprea Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Aprea Therapeutics compare to Aligos Therapeutics?

Aprea Therapeutics (NASDAQ:APRE) and Aligos Therapeutics (NASDAQ:ALGS) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, media sentiment, risk, valuation, institutional ownership, profitability, dividends and analyst recommendations.

: 34.2% of Aprea Therapeutics shares are held by institutional investors. Comparatively, 60.4% of Aligos Therapeutics shares are held by institutional investors. 13.6% of Aprea Therapeutics shares are held by company insiders. Comparatively, 4.8% of Aligos Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
: Aligos Therapeutics has a net margin of -1,106.72% compared to Aprea Therapeutics' net margin of -4,405.59%. Aligos Therapeutics' return on equity of -28.16% beat Aprea Therapeutics' return on equity.
Company Net Margins Return on Equity Return on Assets
Aprea Therapeutics -4,405.59% -96.33% -74.35%
Aligos Therapeutics -1,106.72% -28.16% -20.01%
: Aprea Therapeutics presently has a consensus price target of $4.10, suggesting a potential upside of 386.24%. Aligos Therapeutics has a consensus price target of $41.50, suggesting a potential upside of 553.54%. Given Aligos Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Aligos Therapeutics is more favorable than Aprea Therapeutics.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Aprea Therapeutics
1 Sell rating(s)
1 Hold rating(s)

2 Buy rating(s)

0 Strong Buy rating(s)
2.25
Aligos Therapeutics
1 Sell rating(s)

0 Hold rating(s)

3 Buy rating(s)

1 Strong Buy rating(s)
2.80
: In the previous week, Aprea Therapeutics and Aprea Therapeutics both had 1 articles in the media. Aligos Therapeutics' average media sentiment score of 0.27 beat Aprea Therapeutics' score of 0.00 indicating that Aligos Therapeutics is being referred to more favorably in the news media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Aprea Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Aligos Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
: Aprea Therapeutics has a beta of 1.48, indicating that its share price is 48% more volatile than the S&P 500. Comparatively, Aligos Therapeutics has a beta of 2.28, indicating that its share price is 128% more volatile than the S&P 500.
: Aprea Therapeutics has higher earnings, but lower revenue than Aligos Therapeutics. Aligos Therapeutics is trading at a lower price-to-earnings ratio than Aprea Therapeutics, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Aprea Therapeutics $290K 36.00 -$12.60M -$1.98 N/A
Aligos Therapeutics $2.19M 17.95 -$24.19M -$8.59 N/A

Company	Net Margins	Return on Equity	Return on Assets
Aprea Therapeutics	-4,405.59%	-96.33%	-74.35%
Aligos Therapeutics	-1,106.72%	-28.16%	-20.01%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aprea Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Aligos Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aprea Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Aligos Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aprea Therapeutics	$290K	36.00	-$12.60M	-$1.98	N/A
Aligos Therapeutics	$2.19M	17.95	-$24.19M	-$8.59	N/A

Summary

Aligos Therapeutics beats Aprea Therapeutics on 11 of the 16 factors compared between the two stocks.

How does Aprea Therapeutics compare to RenovoRx?

RenovoRx (NASDAQ:RNXT) and Aprea Therapeutics (NASDAQ:APRE) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, earnings, institutional ownership, profitability, valuation, analyst recommendations, risk and dividends.

: RenovoRx presently has a consensus target price of $8.25, suggesting a potential upside of 788.72%. Aprea Therapeutics has a consensus target price of $4.10, suggesting a potential upside of 386.24%. Given RenovoRx's stronger consensus rating and higher possible upside, equities analysts clearly believe RenovoRx is more favorable than Aprea Therapeutics.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
RenovoRx
1 Sell rating(s)
0 Hold rating(s)

2 Buy rating(s)

1 Strong Buy rating(s)
2.75
Aprea Therapeutics
1 Sell rating(s)

1 Hold rating(s)

2 Buy rating(s)

0 Strong Buy rating(s)
2.25
: RenovoRx has higher revenue and earnings than Aprea Therapeutics. RenovoRx is trading at a lower price-to-earnings ratio than Aprea Therapeutics, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
RenovoRx $1.12M 37.34 -$11.17M -$0.32 N/A
Aprea Therapeutics $290K 36.00 -$12.60M -$1.98 N/A
: RenovoRx has a net margin of -994.48% compared to Aprea Therapeutics' net margin of -4,405.59%. Aprea Therapeutics' return on equity of -96.33% beat RenovoRx's return on equity.
Company Net Margins Return on Equity Return on Assets
RenovoRx -994.48% -119.77% -91.25%
Aprea Therapeutics -4,405.59% -96.33% -74.35%
: 3.1% of RenovoRx shares are held by institutional investors. Comparatively, 34.2% of Aprea Therapeutics shares are held by institutional investors. 9.1% of RenovoRx shares are held by company insiders. Comparatively, 13.6% of Aprea Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
: RenovoRx has a beta of 1, indicating that its stock price has a similar volatility profile to the S&P 500.Comparatively, Aprea Therapeutics has a beta of 1.48, indicating that its stock price is 48% more volatile than the S&P 500.
: In the previous week, RenovoRx had 1 more articles in the media than Aprea Therapeutics. MarketBeat recorded 2 mentions for RenovoRx and 1 mentions for Aprea Therapeutics. RenovoRx's average media sentiment score of 0.00 equaled Aprea Therapeutics'average media sentiment score.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
RenovoRx
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Aprea Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
RenovoRx	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75
Aprea Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
RenovoRx	$1.12M	37.34	-$11.17M	-$0.32	N/A
Aprea Therapeutics	$290K	36.00	-$12.60M	-$1.98	N/A

Company	Net Margins	Return on Equity	Return on Assets
RenovoRx	-994.48%	-119.77%	-91.25%
Aprea Therapeutics	-4,405.59%	-96.33%	-74.35%

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
RenovoRx	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Aprea Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

RenovoRx beats Aprea Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Aprea Therapeutics compare to INmune Bio?

INmune Bio (NASDAQ:INMB) and Aprea Therapeutics (NASDAQ:APRE) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, valuation, analyst recommendations, earnings, media sentiment, profitability, institutional ownership and dividends.

: 12.7% of INmune Bio shares are held by institutional investors. Comparatively, 34.2% of Aprea Therapeutics shares are held by institutional investors. 21.0% of INmune Bio shares are held by company insiders. Comparatively, 13.6% of Aprea Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
: INmune Bio has a net margin of 0.00% compared to Aprea Therapeutics' net margin of -4,405.59%. Aprea Therapeutics' return on equity of -96.33% beat INmune Bio's return on equity.
Company Net Margins Return on Equity Return on Assets
INmune Bio N/A -109.53% -83.34%
Aprea Therapeutics -4,405.59% -96.33% -74.35%
: Aprea Therapeutics has higher revenue and earnings than INmune Bio. INmune Bio is trading at a lower price-to-earnings ratio than Aprea Therapeutics, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
INmune Bio $50K 818.66 -$45.93M -$1.90 N/A
Aprea Therapeutics $290K 36.00 -$12.60M -$1.98 N/A
: INmune Bio has a beta of 1.04, indicating that its stock price is 4% more volatile than the S&P 500. Comparatively, Aprea Therapeutics has a beta of 1.48, indicating that its stock price is 48% more volatile than the S&P 500.
: In the previous week, INmune Bio had 3 more articles in the media than Aprea Therapeutics. MarketBeat recorded 4 mentions for INmune Bio and 1 mentions for Aprea Therapeutics. INmune Bio's average media sentiment score of 0.00 equaled Aprea Therapeutics'average media sentiment score.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
INmune Bio
0 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Aprea Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
: INmune Bio currently has a consensus price target of $8.00, indicating a potential upside of 419.48%. Aprea Therapeutics has a consensus price target of $4.10, indicating a potential upside of 386.24%. Given INmune Bio's higher possible upside, research analysts plainly believe INmune Bio is more favorable than Aprea Therapeutics.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
INmune Bio
2 Sell rating(s)
2 Hold rating(s)

1 Buy rating(s)

1 Strong Buy rating(s)
2.17
Aprea Therapeutics
1 Sell rating(s)

1 Hold rating(s)

2 Buy rating(s)

0 Strong Buy rating(s)
2.25

Company	Net Margins	Return on Equity	Return on Assets
INmune Bio	N/A	-109.53%	-83.34%
Aprea Therapeutics	-4,405.59%	-96.33%	-74.35%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
INmune Bio	$50K	818.66	-$45.93M	-$1.90	N/A
Aprea Therapeutics	$290K	36.00	-$12.60M	-$1.98	N/A

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
INmune Bio	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Aprea Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
INmune Bio	2 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.17
Aprea Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Summary

Aprea Therapeutics beats INmune Bio on 9 of the 16 factors compared between the two stocks.

Get Aprea Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding APRE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

APRE vs. The Competition

Export

Metric	Aprea Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$10.41M	$3.40B	$6.25B	$11.77B
Dividend Yield	N/A	2.23%	2.74%	5.26%
P/E Ratio	-0.43	22.62	24.91	23.23
Price / Sales	36.00	280.78	504.56	75.49
Price / Cash	N/A	125.06	43.30	53.90
Price / Book	0.55	7.05	9.67	6.69
Net Income	-$12.60M	$23.62M	$3.55B	$332.64M
7 Day Performance	0.75%	3.67%	1.70%	2.01%
1 Month Performance	17.86%	7.17%	5.62%	9.19%
1 Year Performance	-51.82%	67.04%	34.42%	39.59%

Aprea Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
APRE Aprea Therapeutics	3.3261 of 5 stars	$0.84 +0.3%	$4.10 +386.2%	N/A	$10.41M	$290K	N/A	7	Gap Up
ATHE Alterity Therapeutics	0.9237 of 5 stars	$4.58 -0.9%	N/A	N/A	$40.97M	N/A	N/A	10
HOWL Werewolf Therapeutics	2.6204 of 5 stars	$0.74 -10.8%	$3.75 +406.8%	N/A	$40.33M	$1.88M	N/A	40	News Coverage Upcoming Earnings Insider Trade Gap Up High Trading Volume
ALGS Aligos Therapeutics	3.6895 of 5 stars	$6.29 -2.2%	$41.50 +559.8%	N/A	$39.79M	$2.19M	N/A	90	Upcoming Earnings
RNXT RenovoRx	2.8814 of 5 stars	$0.84 -3.5%	$8.25 +882.1%	N/A	$39.20M	$1.12M	N/A	6	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:APRE) was last updated on 5/5/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Aprea Therapeutics (APRE) Competitors

APRE vs. ATHE, HOWL, ALGS, RNXT, and INMB

How does Aprea Therapeutics compare to Alterity Therapeutics?

Summary

How does Aprea Therapeutics compare to Werewolf Therapeutics?

Summary

How does Aprea Therapeutics compare to Aligos Therapeutics?

Summary

How does Aprea Therapeutics compare to RenovoRx?

Summary

How does Aprea Therapeutics compare to INmune Bio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

APRE vs. The Competition

Aprea Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Aprea Therapeutics (APRE) Competitors

APRE vs. ATHE, HOWL, ALGS, RNXT, and INMB

How does Aprea Therapeutics compare to Alterity Therapeutics?

Summary

How does Aprea Therapeutics compare to Werewolf Therapeutics?

Summary

How does Aprea Therapeutics compare to Aligos Therapeutics?

Summary

How does Aprea Therapeutics compare to RenovoRx?

Summary

How does Aprea Therapeutics compare to INmune Bio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

APRE vs. The Competition

Aprea Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools